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1 recognized
almost 200 years ago that pro-
teinuria accompanied renal failure.
The detection limits of both pro-
teinuria and reduced glomerular
ﬁltration rate (GFR) have moved
ever lower since then. Even modest
amounts of albuminuria above 30
mg/g of urine creatinine pose a risk
of future renal function loss.2 This
raises the important question of
whether screening for signiﬁcant
renal disease should include testing
for even lower amounts of
albuminuria.
Melsom et al.3 report the risk of
renal function loss in subjects who
have amounts of urinary albumin
excretion that are below the
accepted lower level of normal.
Their population included 1278
white individuals aged 50 to 62
years, free of diabetes mellitus or
cardiovascular disease, with normal
measured GFR by iohexol clearance
and followed for more than 5 years.
The quality of the urine collection
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taking the average of 3 ﬁrst-void
morning spot urines. The popula-
tion showed very low albumin-to-
creatinine ratios. An increased risk
of loss of renal function is reported
in this cohort, as their amount
of albumin-to-creatinine ratio
increased from none, to 0.1 to 0.45
and to 0.46 to 3.4mg urine albumin/
mmol urine creatinine. The results
of Melsom et al.3 are intriguing, yet
appear to have ﬂaws of internal and
external validity.
The assay method for albumin-
uria that was used in this report has
a limit of quantitation that is 7.5
mg/l. That corresponds to approx-
imately 7.5 mg/g of urine creati-
nine, which in turn corresponds to
approximately 0.75 mg urine albu-
min/mmol urine creatinine. This
assay’s detection limit is 2 mg/l. In
the range between 2.0 and 7.5 mg/l,
this assay thus does not have
quantitative precision. Melsom
et al.3 report that subjects in their
study with albuminuria in this
range had increased loss of GFR
over the 5-year follow-up time of
their study, and this was in a
graded fashionwithin that very low
range of albuminuria. Their claims
may thus be disputed because of the769expected imprecision of the assay in
that very low range. The present
report does not record whether the
study subjects had urinalyses. If
there was more microhematuria in
those with greater albuminuria, or
if there was pyuria, then there is
likely to have been more urinary
tract pathology that would explain
the loss of renal function, rather
than just a modestly increased
amount of urine albumin.
External validity is another
concern. The study population was
entirely white. Their average base-
line GFR was above 90 ml/min per
1.73 m2. One may not be able to
apply these ﬁndings to a more
diverse population or to those with
lower GFR. Also, the yearly inci-
dence of new end-stage renal disease
in Norway is 100/million popula-
tion, which is well below that of the
United States and also below that of
Belgium, which is 380 and 180,
respectively (https://www.usrds.
org/2017/view/v2_11.aspx).
It is also worth considering the
rates of loss of GFR over the study
follow-up time, as shown in
Figure 2 of Melsom et al.3 The rate
of loss of GFR in those with no
albuminuria was approximately
0.5 ml/min per year, and was
approximately 1 ml/min per year
in those with 0.1 to 3.4 mg
albumin/mmol urine creatinine.
These rates are well below the rates
of loss of GFR in subjects with
chronic progressive kidney disease
(Figure 1). Also, the subjects of this
study had an average age of 58 at
the start of the study, so would be
63 years old at end of the study.
On average, they will live for 20
more years. At a rate of 1 ml/min
per year, the subjects in the 0.1 to
3.4 mg urine albumin/mmol urine
creatinine group would have a GFR
of approximately 78 ml/min at
their 20-year follow-up time, when




















Figure 1. Rate of loss of glomerular ﬁltra-
tion rate (GFR), in ml/min per year, as a
function of degree of albuminuria. Data
adapted from Melsom et al.3 The rates of
loss of GFR for study subjects with no
albuminuria and 0.1 to 3.4 mg albuminuria/
mmol urine creatinine are shown as the left
and right black columns. The grey shading
shows rates of yearly loss of GFR in pro-
gressive chronic kidney disease. The rates
of loss of GFR in the study subjects are well
below those of patients with progressive
chronic kidney disease.
COMMENTARY EP Cohen and J-M Krzesinski: Low-Grade AlbuminuriaA GFR in that range at that age is
not renal failure and has no sig-
niﬁcant effect on all-cause mortal-
ity.4 The report by Melsom et al.3
may be telling us something
about aging, but it may not be
signiﬁcant with regard to risk of
renal failure or death.770In a broader perspective, the
effort to categorize renal function
according to estimated GFR and
urinary albumin excretion may be
distracting us fromﬁnding the cause
of a patient’s renal disease. We may
have some satisfaction to record the
precise label of stage as G2A1 or
G4A3, for instance, but if we don’t
know the cause of our patient’s renal
disease, we are not much further in
our understanding than was
Bright,1 200 years ago. Diagnosis of
chronic kidney disease and predic-
tion of further loss of renal function
depends on interpreting the urinal-
ysis and graphing the fall in GFR
versus time, to which are added the
renal biopsy and even urine prote-
omics.5 This will move us beyond
mere categories of chronic kidney
disease, and will ensure better care
of our patients. Measuring albumin-
to-creatinine ratio remains useful for
predicting the future loss of renal
function, but at very low levels it
appears of minor clinical interest.
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